arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Mineralys Therapeutics, Inc.

MLYS
$15.25 ▼ -1.75 (-10.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

Mineralys Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -35.3% ↘
FCF / Share $-0.38 ↗
Trailing P/E —
Price / Book 2.5x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-39.34M
↑ +6.8% —
FCF / Share Free cash flow per share
$-0.38
↑ +19.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
26
Cash Quality ↓
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 19 quarters